Muscarinic Agonists as Cognitive Enhancers
A method of treating a mental condition in a subject in need thereof, comprising: administering to a subject in need thereof an effective amount of compound CDD-102A.
1 . A composition comprising an effective amount of a CDD-0102 [5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine] compound, or a pharmaceutically acceptable salt or hydrate thereof sufficient to enhance behavioral flexibility by enhancing one or more of executive functioning, reasoning, problem solving, and learning functioning in a subject in need thereof.
2 . (canceled)
3 . (canceled)
4 . The composition according to claim 1 , wherein the behavioral flexibility function includes one or more of: perseveration errors, regressive errors and never-reinforced errors.
5 . The composition according to claim 1 , wherein the administration of the compound gives rise to efficacious treatment without substantially interfering with M 2 , M 3 , M 4 and M 5 receptor activity in the subject.
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . The pharmaceutical composition according to claim 1 , formulated to be administered to a subject in need thereof in a dosage ranging from about 0.001 mg/kg to about 10 mg/kg body weight.
10 . The pharmaceutical composition according to claim 1 , formulated to be administered to a subject in need thereof in a dosage ranging from about 0.01 to about 10 mg/kg of body weight.
11 . The pharmaceutical composition according to claim 1 , formulated to be administered to a subject in need thereof in a dosage ranging from about 0.01 mg/kg to about 0.1 mg/kg of body weight.
12 . The pharmaceutical composition according to claim 1 , formulated to be administered to a subject in need thereof in a daily dosage.
13 . The pharmaceutical composition according to claim 1 , formulated to be administered to a subject in need thereof in a regimen of 1 to 4 times per day.
14 . (canceled)
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . (canceled)
19 . (canceled)
20 . (canceled)
21 . (canceled)
22 . (canceled)
23 . (canceled)
24 . (canceled)
25 . (canceled)
26 . (canceled)
27 . (canceled)
28 . (canceled)
29 . (canceled)
30 . (canceled)
31 . A method of improving and/or modulating a loss of behavioral flexibility in a subject in need thereof, comprising:
administering to a subject in need thereof an effective amount of CDD-102A [5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine] compound or a pharmaceutically acceptable salt or hydrate thereof,
sufficient to enhance behavioral flexibility by enhancing one or more of: executive function, reasoning and problem solving, a memory function, a learning function.
32 . The method according to claim 31 , wherein the behavioral flexibility function includes one or more of: perseveration errors, regressive errors and never-reinforced errors.
33 . The method according to claim 31 , wherein the administration of the compound gives rise to efficacious treatment without substantially interfering with M 2 , M 3 , M 4 and/or M 5 subtype receptor activity in the subject.
34 . The method according to claim 31 , wherein the mental condition is at least partially due to decreased M 1 receptor activity.
35 . The method according to claim 31 , wherein the subject has a mental condition selected from the group consisting of one or more of: neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, schizophrenia, age-related cognitive decline, and attention-deficit disorder.
36 . (canceled)
37 . (canceled)
38 . (canceled)
39 . (canceled)
40 . (canceled)
41 . (canceled)
42 . (canceled)
43 . (canceled)
44 . (canceled)
45 . The method according to claim 31 , wherein the subject is a human.
46 . (canceled)
47 . (canceled)
48 . (canceled)
49 . (canceled)
50 . Use of CDD-102A [5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine] compound or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising CDD-102A [5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine] compound or a pharmaceutically acceptable salt or hydrate thereof in the manufacture of a medicament for use in improving and/or ameliorating a loss of behavioral flexibility in a subject in need thereof.
51 . (canceled)
52 . (canceled)
53 . (canceled)
54 . Use of CDD-102A compound or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising CDD-102A compound or a pharmaceutically acceptable salt or hydrate thereof, in the manufacture of a medicament for treating a mental condition affecting behavioral flexibility in a subject.
55 . (canceled)
56 . Use according to claim 54 ,
wherein the mental condition is selected from the group consisting of one or more of: neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, schizophrenia, age-related cognitive decline, and attention-deficit disorder.
57 . (canceled)
58 . (canceled)
59 . (canceled)
60 . (canceled)
61 . (canceled)
62 . (canceled)
63 . (canceled)
64 . (canceled)
65 . (canceled)
66 . (canceled)
67 . (canceled)
68 . (canceled)
69 . (canceled)
70 . (canceled)
71 . (canceled)
72 . (canceled)
73 . Use according to claim 54 ,
wherein the use includes preventing the development of the condition, and/or whereby the condition has already developed and the subject is protected against worsening of the condition.
74 . Use according to claim 54 ,
wherein the disease or condition results from defective or malfunctioning M 1 receptors in the subject.
75 . Use according to claim 54 ,
wherein the treatment disease or condition results from suppressed M 1 receptor transmission in the subject.
76 . Use according to claim 54 ,
for use in selectively activating M 1 muscarinic receptor, without substantially interfering with M 2 , M 3 , M 4 and M 5 receptor activity.
77 . (canceled)
78 . (canceled)
79 . (canceled)
80 . (canceled)
81 . Use according to claim 54 , wherein the subject is a human.